jCyte Announces Appointment of Dr. Adam Walsh as Chief Financial Officer

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--jCyte, Inc., a private biotechnology company dedicated to improving the lives of patients with retinal degenerative diseases, announced the further expansion of the company’s executive management team with the appointment of Adam Walsh, M.D. as Chief Financial Officer. Dr. Walsh brings to jCyte over two decades of Wall Street experience as both an award-winning biotechnology equity research analyst and investment banker, and a strong foundation in corporate finance and strategy with outstanding corporate and institutional relationships across the sector.

Prior to joining jCyte, Dr. Walsh was Chief Financial Officer of Catalytic Life Sciences, LLC, an investment bank focused exclusively on biotechnology fundraising and M&A. From October 2015 to July 2020, Dr. Walsh was Managing Director and Senior Analyst, Biotechnology Equity Research at Stifel, where he earned multiple Thomson Reuters StarMine awards for his analysis, including #1 Top Stock Picker and #2 Top Earnings Estimator for the Biotechnology Sector. Dr. Walsh began his sell-side career at Jefferies (2002-2008), where he was the founding Managing Director of Jefferies’ Biotechnology Equity Research platform. Dr. Walsh received his M.D. and M.B.A. degrees from Tufts University and his B.A. and B.S. in Psychology and Business Administration from the University of Colorado, Boulder.

“I am delighted to welcome Dr. Walsh to the jCyte team. The addition of Dr. Walsh brings to jCyte a highly experienced Wall Street veteran with a diverse skill set, excellent relationships, and a proven track record of success. His unique professional background as a physician, analyst and banker makes Adam an ideal fit for jCyte at this key inflection point in the Company’s evolution as we prepare to initiate our global Phase 3 program for jCell’s lead indication, retinitis pigmentosa (RP), and advance our FDA designated Regenerative Medicine Advanced Therapy (RMAT) into other follow-on retinal degenerative indications,” said Dr. Shannon Blalock, Chief Executive Officer, jCyte.

“I am thrilled to join jCyte and look forward to working closely with its team of highly skilled professionals with decades of pharmaceutical industry experience to ensure we successfully deliver our transformative jCell platform therapy to the many RP patients who currently have no treatment options, and for the many patients suffering with other retinal degenerative conditions,” noted Dr. Adam Walsh

jCell is a first-in-class investigational treatment for RP which has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation. In addition to RMAT designation, jCell has received Orphan Drug designation from the FDA and the European Medicines Agency (EMA).

About jCyte, Inc.

jCyte, Inc. is a clinical-stage biotech company focused on developing its first-in-class regenerative cell therapy, jCell, for retinitis pigmentosa (RP) and other retinal degenerative disorders. The treatment is minimally invasive and given as an intravitreal injection. There are currently no FDA approved therapies for RP. The Company is pioneering a new era of regenerative therapies to address the significant unmet medical needs of patients suffering from a broad set of retinal degenerative diseases. For more information, visit www.jcyte.com.